Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent RSV + HMPV protein vaccine
- Development stage
- Unknown
- Lead developer
- Vicebio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The bivalent RSV + HMPV protein vaccine (RPF08203) is an investigational combination vaccine candidate being developed by Sanofi to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). Originally developed by Vicebio using its proprietary second-generation molecular clamp (MC2S) technology, the vaccine consists of recombinantly expressed fusion (F) glycoproteins from both RSV and HMPV stabilized in their native prefusion conformation. This structural stabilization is designed to elicit robust neutralizing antibody responses against both pathogens, which are leading causes of severe respiratory illness, hospitalization, and death in older adults and immunocompromised populations. The vaccine is currently being evaluated in a Phase 2b clinical study to assess its efficacy, safety, and immunogenicity in adults aged 60 years and older.
- Other names
- bivalent RSV+HMPV protein vaccineRSV-HMPV bivalent vaccineRSV/hMPV bivalent vaccine
02
Targets
HMPV F (Human metapneumovirus fusion protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on bivalent RSV + HMPV protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent RSV + HMPV protein vaccine.